SHLT Stock Overview
Develops and markets personal telemedicine solutions in Israel, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
SHL Telemedicine Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 2.84 |
| 52 Week High | CHF 9.48 |
| 52 Week Low | CHF 2.54 |
| Beta | 0.40 |
| 11 Month Change | 1.10% |
| 3 Month Change | -24.82% |
| 1 Year Change | -68.26% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -86.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| SHLT | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -1.7% | -5.1% | -2.1% |
| 1Y | -68.3% | 3.0% | 29.7% |
Return vs Industry: SHLT underperformed the US Healthcare industry which returned 2.9% over the past year.
Return vs Market: SHLT underperformed the US Market which returned 29.6% over the past year.
Price Volatility
| SHLT volatility | |
|---|---|
| SHLT Average Weekly Movement | 11.4% |
| Healthcare Industry Average Movement | 6.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SHLT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SHLT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 583 | David Arnon | www.shl-telemedicine.com |
SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen’C, a personal cellular-digital 12-lead ECG transmitter device; and Cardio’B, a portable device to transmit a 12-lead ECG. The company also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices, including blood pressure, weighing, oxygen saturation level (TelePulse Oximeter), breath exhalation (TeleBreather), and sugar measuring devices; and TelePress, a remote blood pressure monitoring device for personal use.
SHL Telemedicine Ltd. Fundamentals Summary
| SHLT fundamental statistics | |
|---|---|
| Market cap | US$45.76m |
| Earnings (TTM) | -US$8.84m |
| Revenue (TTM) | US$55.94m |
0.8x
P/S Ratio-5.2x
P/E RatioIs SHLT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SHLT income statement (TTM) | |
|---|---|
| Revenue | US$55.94m |
| Cost of Revenue | US$30.36m |
| Gross Profit | US$25.58m |
| Other Expenses | US$34.42m |
| Earnings | -US$8.84m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 45.73% |
| Net Profit Margin | -15.80% |
| Debt/Equity Ratio | 15.9% |
How did SHLT perform over the long term?
See historical performance and comparison